论文信息 - Tocilizumab in COVID-19: finding the optimal route and dose - 字舞流文

Tocilizumab in COVID-19: finding the optimal route and dose

ShefaliKhanna Sharma | Siddharth Jain | S. Jain

[1] ShefaliKhanna Sharma,et al. Rational use of tocilizumab in COVID-19 , 2020, Annals of the Rheumatic Diseases.

[2] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[3] F. Costanzo,et al. Use of subcutaneous tocilizumab in patients with COVID‐19 pneumonia , 2020, Journal of medical virology.

[4] Giuseppe Magro,et al. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc , 2020, Cytokine: X.

[5] R. Desai,et al. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. , 2020, The Lancet. Rheumatology.

[6] E. Favalli. Tofacitinib's infectious profile: concerns for clinical practice , 2020 .

[7] Xiaoping Zhang,et al. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. , 2013, International journal of clinical pharmacology and therapeutics.

[8] F. Steele. Assessment Report for the , 1996 .